Fused PET/CT systems outperform PET or CT alone
This article was originally published in Clinica
PET/CT hybrids are more accurate in staging tumours compared to either modality alone, according to data presented at last month's European Congress of Radiology (ECR) in Vienna. Approximately 90% of the PET/CT market is now dominated by hybrid PET/CT systems, according to industry experts (see Clinica No 1150, p 22).
You may also be interested in...
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.